Plaque Psoriasis

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

New findings from the POSITIVE trial highlight tildrakizumab's effectiveness in enhancing quality of life for psoriatic disease patients.

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

These late-breaking data at EADV highlight predictive factors for early super response to treatment with bimekizumab for psoriasis.

This interview segment highlights Song’s risankizumab data covered during the 2025 EADV Congress in Paris.

Icotrokinra outperforms deucravacitinib in achieving skin clearance for plaque psoriasis, offering a promising new oral treatment option.

Eingun James Song, MD, highlights recent phase 4 data on risankizumab for patients with moderate to severe scalp and genital psoriasis.

This letter explores off-label dosing adjustments for patients with psoriasis using the IL-17A inhibitors secukinumab and ixekizumab.

In this study, investigators assessed how the prescription patterns of biologics, non-biologic systemic agents, and phototherapy are altered after cardiovascular events.

These data underscore the value of individualized cancer risk evaluations when selecting treatment strategies for psoriasis.

A look at 13 phase 2 and phase 3 studies with significant implications from EADV 2025's late-breaking sessions.

Investigators systematically reviewed NB-UVB treatment responses for psoriasis in patients with skin of color.

In this observational analysis, investigators highlight the potential causal link identified between NHHR and psoriasis development.

An audio recap of the top 5 stories in healthcare news from the week of 08/31-9/5.

Investigators highlighted the cardiovascular safety of systemic treatments for psoriasis such as methotrexate and tumor necrosis factor inhibitors.

This analysis highlights bimekizumab’s impact on psoriasis clearance compared to ustekinumab, secukinumab, and adalimumab.

This announcement regarding the new sNDA for roflumilast cream in pediatric patients with psoriasis follows positive findings from the MUSE study.

In this analysis, investigators looked at the importance of skin clearance and daily time trade off (dTTO) among adult patients living with chronic hand eczema (CHE).

This analysis looked at a Hispanic patient cohort, systematically linking specific trichoscopic patterns with clinical outcomes related to scalp psoriasis.

Multidisciplinary management and patient-centered care are critical for optimizing outcomes in complex or severe psoriasis cases.

This analysis suggests that this AI model effectively classifies skin irritation in patch tests, allowing for quicker and more accurate dermatologic assessments.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.

These findings on teledermatology highlight its effectiveness as a potential solution for disparities in dermatology care within rural communities.

These data on roflumilast cream 0.3% highlight the medication’s efficacy and safety in pediatric patients aged 2 - 11 years.